In vitro and in vivo effects of fulvestrant combined with trastuzumab in breast cancer with estrogen receptor-positive and HER-2/neu-overexpressing

被引：0
|
作者：
Chen, Q. [1 ]
Wu, K. [1 ]
Lu, Y. [1 ]
Ding, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Gen Surg, Shanghai 200030, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页码：S121 / S122
页数：2
相关论文
共 50 条
  • [31] Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy
    Shiau, Ai-Li
    Lin, Yu-Ping
    Shieh, Gia-Shing
    Su, Chih-Hau
    Wu, Wen-Luan
    Tsai, Yuh-Shyan
    Cheng, Chih-Wei
    Lai, Ming-Derg
    Wu, Chao-Liang
    MOLECULAR THERAPY, 2007, 15 (01) : 131 - 138
  • [32] Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells
    Wang, Jing
    Yang, Qifeng
    Haffty, Bruce G.
    Li, Xiaoyan
    Moran, Meena S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 431 (02) : 146 - 151
  • [33] Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast
    Sastre-Garau, X
    Genin, P
    Rousseau, A
    Al Ghuzlan, A
    Nicolas, A
    Fréneaux, P
    Rosty, C
    Sigal-Zafrani, B
    Couturier, J
    Thiery, JP
    Magdelénat, H
    Vincent-Salomon, A
    HISTOPATHOLOGY, 2004, 45 (02) : 142 - 147
  • [34] Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 78 - 83
  • [35] HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
    Love, RR
    Duc, NB
    Havighurst, TC
    Mohsin, SK
    Zhang, Q
    DeMets, DL
    Allred, DC
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) : 453 - 457
  • [36] FULVESTRANT COMBINED WITH CAPECITABINE MAY BE EFFECTIVE AND WELL TOLERATED FOR PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER
    Nakai, Maki
    BREAST, 2015, 24 : S50 - S51
  • [37] Trastuzumab (Herceptin®):: Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
    Ditsch, Nina
    Rueckert, Sandra
    Kuemper, Carolin
    Lenhard, Miriam
    Kahlert, Steffen
    Bauerfeind, Ingo
    Friese, Klaus
    Untch, Michael
    BREAST CARE, 2006, 1 (02) : 78 - 84
  • [38] Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer
    Schwartz, GN
    Kaufman, PA
    Tretter, CPG
    Arrick, BA
    Mulrooney, TJ
    Connelly, EM
    Mellinger, DL
    Fisher, JL
    Ernsloff, MS
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
  • [39] Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
    Gritzapis, AD
    Perez, SA
    Baxevanis, CN
    Papamichail, M
    BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 72 - 79
  • [40] Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer
    Hung, MC
    Hortobagyi, GN
    Ueno, NT
    CANCER GENE THERAPY, 2000, 465 : 171 - 180
12345